[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646807":3},{"organization":4,"armGroups":7,"interventions":45,"overallOfficials":11,"centralContacts":63,"locations":11,"responsibleParty":69,"collaborators":11,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":11,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":11,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":11,"overallStatus":90,"whyStopped":11,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":11},{"fullName":5,"class":6},"Kubota Vision Inc.","INDUSTRY",[8,18,21,24,27,30,33,36,39,42],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence 1","EXPERIMENTAL",null,[13,14,15,16,17],"Device: KG1","Device: KG2","Device: KG3","Device: KG4","Device: KG5",{"label":19,"type":10,"description":11,"interventionNames":20},"Sequence 2",[13,14,15,16,17],{"label":22,"type":10,"description":11,"interventionNames":23},"Sequence 3",[13,14,15,16,17],{"label":25,"type":10,"description":11,"interventionNames":26},"Sequence 4",[13,14,15,16,17],{"label":28,"type":10,"description":11,"interventionNames":29},"Sequence 5",[13,14,15,16,17],{"label":31,"type":10,"description":11,"interventionNames":32},"Sequence 6",[13,14,15,16,17],{"label":34,"type":10,"description":11,"interventionNames":35},"Sequence 7",[13,14,15,16,17],{"label":37,"type":10,"description":11,"interventionNames":38},"Sequence 8",[13,14,15,16,17],{"label":40,"type":10,"description":11,"interventionNames":41},"Sequence 9",[13,14,15,16,17],{"label":43,"type":10,"description":11,"interventionNames":44},"Sequence 10",[13,14,15,16,17],[46,51,54,57,60],{"type":47,"name":48,"description":49,"armGroupLabels":50,"otherNames":11},"DEVICE","KG1","Unique Kubota Glass optical defocus parameter",[9,43,19,22,25,28,31,34,37,40],{"type":47,"name":52,"description":49,"armGroupLabels":53,"otherNames":11},"KG2",[9,43,19,22,25,28,31,34,37,40],{"type":47,"name":55,"description":49,"armGroupLabels":56,"otherNames":11},"KG3",[9,43,19,22,25,28,31,34,37,40],{"type":47,"name":58,"description":49,"armGroupLabels":59,"otherNames":11},"KG4",[9,43,19,22,25,28,31,34,37,40],{"type":47,"name":61,"description":49,"armGroupLabels":62,"otherNames":11},"KG5",[9,43,19,22,25,28,31,34,37,40],[64],{"name":65,"role":66,"phone":67,"phoneExt":11,"email":68},"Kubota Vision","CONTACT","425-527-3260","boconnor@kubotavision.com",{"type":70,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100646807","a-controlled-evaluation-of-optical-defocus-parameters-on-transient-changes-in-axial-length-using-kubota-glass-100646807",false,"NCT07686289","A Controlled Evaluation of Optical Defocus Parameters on Transient Changes in Axial Length Using Kubota Glass","Inclusion Criteria:\n\n* Be of legal age or, if under legal age have written consent of their parent or guardian to participate.\n* Sign written Informed Consent (and the California Bill of Rights, if applicable).\n* Be between age 8-24 (inclusive) and able to understand and assent to participation.\n* Have a spherical component of spectacle prescription between -1.00 and -5.00 diopters (D) (inclusive) in each eye.\n* Have a refractive astigmatism of less than or equal to -1.00 D in each eye.\n* Have axial length between 23.00 and 25.99 millimeters (mm) in each eye.\n* Best Spectacle Corrected Visual Acuity (BSCVA) of 20\u002F25 or better in each eye.\n* Be willing and able to follow instructions and attend the schedule of follow-up visits.\n\nExclusion Criteria:\n\n* Unable or unwilling to provide informed consent and assent.\n* Eye injury or surgery within twelve weeks immediately prior to enrollment.\n* Currently enrolled in an ophthalmic clinical trial.\n* Pregnant or lactating or expect to become pregnant during the trial (by self-report).\n* Evidence of systemic or ocular abnormality, infection or disease.\n* Use of medications that may affect the eye (including, but not limited to, corticosteroids and antimetabolites).\n* Anisometropia ≥ 2.00.\n* Subjects who have undergone corneal refractive surgery.\n* Use atropine or other anticholinergic drug within the past month.\n* Employees or immediate family members of employees of study sites or sponsor.",true,"ALL","8 Years","24 Years",{"count":82,"type":83},35,"ESTIMATED","INTERVENTIONAL",[86],"NA","This study will assess the optimal performance characteristics of optical defocus on transient changes in axial length with Kubota Glass, using a randomized, double-masked, 5-treatment, 5-period crossover design with contralateral eye control.",[89],"Myopia","NOT_YET_RECRUITING","2026-06-30",{"date":93,"type":94},"2026-07-07","ACTUAL",{"date":96,"type":83},"2026-07-06",{"date":98,"type":83},"2026-12-31",{"name":5,"class":6}]